About Assertio Holdings, Inc.
https://www.assertiotx.comAssertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation.
CEO
Mark L. Reisenauer
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-12-26 | Reverse | 1:15 |
| 2021-05-18 | Reverse | 1:4 |
ETFs Holding This Stock
Summary
Showing Top 3 of 22
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
NANTAHALA CAPITAL MANAGEMENT, LLC
Shares:8.81M
Value:$89.95M
VANGUARD GROUP INC
Shares:4.43M
Value:$45.18M
RENAISSANCE TECHNOLOGIES LLC
Shares:2.94M
Value:$30.04M
Summary
Showing Top 3 of 81
About Assertio Holdings, Inc.
https://www.assertiotx.comAssertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $49.46M ▲ | $24.33M ▼ | $11.45M ▲ | 23.14% ▲ | $1.8 ▲ | $17.8M ▲ |
| Q2-2025 | $29.22M ▲ | $26.58M ▼ | $-16.35M ▼ | -55.96% ▼ | $-2.55 ▼ | $-6.38M ▼ |
| Q1-2025 | $26.49M ▼ | $31.93M ▼ | $-13.54M ▼ | -51.12% ▼ | $-2.1 ▼ | $-3.38M ▼ |
| Q4-2024 | $32.18M ▲ | $34.05M ▲ | $-10.48M ▼ | -32.55% ▼ | $-1.65 ▼ | $-2.09M ▼ |
| Q3-2024 | $29.2M | $24.7M | $-2.92M | -10% | $-0.45 | $4.48M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $93.43M ▼ | $319.77M ▲ | $213.97M ▲ | $105.8M ▲ |
| Q2-2025 | $98.18M ▲ | $273.78M ▼ | $180.48M ▲ | $93.3M ▼ |
| Q1-2025 | $87.33M ▼ | $286.43M ▲ | $177.9M ▲ | $108.53M ▼ |
| Q4-2024 | $100.05M ▲ | $284.73M ▲ | $163.65M ▲ | $121.08M ▼ |
| Q3-2024 | $88.58M | $276M | $145.48M | $130.52M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $11.45M ▲ | $-4.77M ▼ | $-3.81M ▲ | $-7K ▲ | $-8.59M ▼ | $-4.77M ▼ |
| Q2-2025 | $-16.35M ▼ | $19.09M ▲ | $-6.94M ▼ | $-69K ▲ | $12.08M ▲ | $19.09M ▲ |
| Q1-2025 | $-13.54M ▼ | $-12.54M ▼ | $-2.94M ▼ | $-111K ▼ | $-15.58M ▼ | $-12.54M ▼ |
| Q4-2024 | $-10.48M ▼ | $11.55M ▲ | $1.12M ▲ | $-59K ▼ | $12.61M ▲ | $11.55M ▲ |
| Q3-2024 | $-2.92M | $-35K | $-6.71M | $-10K | $-6.75M | $-35K |
Revenue by Products
| Product | Q4-2024 | Q3-2024 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 INDOCIN Products | $20.00M ▲ | $10.00M ▼ | $0 ▼ | $10.00M ▲ |
 Product | $90.00M ▲ | $30.00M ▼ | $30.00M ▲ | $30.00M ▲ |
 Product Other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Royalty | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 SPRIX Nasal Spray | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 CAMBIA | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Otrexup | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 Royalties And Milestones | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2024 | Q3-2024 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 CANADA | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Mark L. Reisenauer
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-12-26 | Reverse | 1:15 |
| 2021-05-18 | Reverse | 1:4 |
ETFs Holding This Stock
Summary
Showing Top 3 of 22
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
NANTAHALA CAPITAL MANAGEMENT, LLC
Shares:8.81M
Value:$89.95M
VANGUARD GROUP INC
Shares:4.43M
Value:$45.18M
RENAISSANCE TECHNOLOGIES LLC
Shares:2.94M
Value:$30.04M
Summary
Showing Top 3 of 81